Pembrolizumab plus chemotherapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be over 18 years old at the time of diagnosis
- Have non-small cell lung cancer confirmed by pathology (tissue test)
- Have advanced disease: stage IIIC or stage IV
- Be able to do daily activities with some limitations (ECOG performance status of 2)
- Have blood tests that meet minimum levels (neutrophils, platelets, and liver function); kidney function must be adequate if pemetrexed is used
- Not be unable to get standard platinum chemotherapy: either your usual treatment is not suitable/refused (stage III) or platinum chemotherapy is unsafe or declined (stage IV)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares pembrolizumab (an immunotherapy drug) given alone versus combined with chemotherapy for women with advanced non-small cell lung cancer that has a high level of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if adding chemotherapy improves outcomes.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy can help people with advanced non-small cell lung cancer that carries an EGFR exon 21 mutation and shows PD-L1 expression. The goal is to see if this combination helps shrink tumors or slow cancer growth more effectively.
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.